Wire · opportunities
New Drug Protects People With Celiac Disease From Gluten Damage in Clinical Trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
The drug FB102 has passed a phase 2 clinical trial showing it can protect the intestinal lining of celiac disease patients from damage caused by accidental gluten exposure, a condition currently manageable only by a strict gluten-free diet. The intravenous drug demonstrated better gut protection and reduced inflammation compared to placebo, supporting advancement to phase 3 trials and potential use in other autoimmune diseases.
This Wire brief sits within Fusion42's coverage of Drug Discovery.
◆ ◆ The Wire takeaway
You are seeing the first real drug coming to market that can protect celiac patients from accidental gluten damage, opening a new treatment avenue beyond diet alone. If you work in autoimmune or digestive disorders, this sets a new standard for what therapies can achieve and shifts patient expectations.
◆ Coverage
1 source · 16 Oct 2026
◆ Related on Wire
◆ Topics